Biosyent Inc (OTCPK:BIOYF)
$ 7.35 0.16 (2.23%) Market Cap: 86.42 Mil Enterprise Value: 68.12 Mil PE Ratio: 16.90 PB Ratio: 3.45 GF Score: 98/100

Q4 2018 Biosyent Inc Earnings Call Transcript

Mar 20, 2019 / NTS GMT
Release Date Price: $6.2 (+0.81%)
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello, and welcome to the BioSyent Q4 and Full Year Fiscal '18 Results Presentation. My name is René Goehrum, and I'm the President and CEO of BioSyent.

I want to start today's presentation with a look at our sales EBITDA and net income after tax for the quarter ended December 31. As you can see on the right side of your screen, our sales reached just above $5.9 million. That was essentially flat with year ago but enough to present a new record in quarter of sales. The breakdown for sales for the quarter was a growth of our Canadian pharmaceutical business of 2%, measured in dollars; our International pharmaceutical business was down 2% in dollars; and our legacy business was down 73% for the quarter. The legacy business represents traditionally a small portion of Q4 and certainly, in 2018, it represents an even smaller portion of the year.

Our EBITDA for the quarter was just above $2.1 million. That was up 8% versus year ago. And our net income after tax was $1.67 million, up 15% versus year ago. So this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot